TVGN and TVGNW Related Headlines
Go Back- Tevogen signs letter of intent to evaluate CRO acquisition
- Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization
- Tevogen Bio (TVGN) to Evaluate Potential One-Time Special Cash Dividend
- Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders
- Tevogen expands T cell therapy pipeline across viral and cancer indications
- Tevogen Demonstrates Platform Scalability and Multi-Indication T Cell Pipeline Expansion in 2025
- Tevogen Bio posts 51% reduction in nine-month operating loss
- Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q
- Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston
- Tevogen Bio values TVGN-489 therapy at $9-11 billion
- Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform
- Tevogen Bio estimates pipeline drug value at $250 million for cancer treatment
- Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas
- Tevogen highlights COVID-19 treatment data for immunocompromised patients
- Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2
- REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts
- Tevogen CEO Donates Personal Shares to Support Local Law Enforcement
- Tevogen Bio projects $1 billion launch year revenue for oncology pipeline
- Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to
- REPEAT - Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders
- REPEAT - Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions
- Tevogen reports 60% rise in institutional stock ownership
- Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions
- Tevogen.AI expands Microsoft, Databricks ties for cancer model beta
- Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology
- Tevogen CEO outlines AI expansion and funding in stockholder letter
- Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders
- Tevogen Bio to receive $1 million grant for AI drug discovery expansion
- Tevogen Bio to Accept $1 Million Additional Grant Funding for AI Expansion
- Tevogen Bio reports 74% insider ownership of outstanding shares
- Tevogen Highlights 74% Insider Ownership, Reinforcing Long-Term Vision
- Tevogen develops AI model to accelerate immunotherapy research
- Tevogen.AI Applauds U.S. Government’s AI Action Plan; Reaffirms Commitment to Accelerating AI Innovation in Healthcare
- Tevogen receives international patent publication for AI peptide prediction technology
- Tevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active Peptides
- Tevogen.AI Targets Faster Time-to-Market with AI-Powered Patient Matching Following PredicTcell™ Alpha Launch
- Tevogen’s New Headquarters, Fully Funded by CEO, Centralizes R&D and AI Teams to Accelerate Innovation
- Tevogen CEO Contributes to Build-Out and First-Year Operations of New Headquarters
- Tevogen Expands Headquarters Amid Growth of AI and Generics & Biosimilars Initiatives
TVGN and TVGNW Related Press Releases
Go Back- Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization
- Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders
- Tevogen Demonstrates Platform Scalability and Multi-Indication T Cell Pipeline Expansion in 2025
- Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q
- Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston
- Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform
- Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas
- Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2
- REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts
- Tevogen CEO Donates Personal Shares to Support Local Law Enforcement
- Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to
- REPEAT - Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders
- REPEAT - Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions
- Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions
- Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology
- Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders
- Tevogen Bio to Accept $1 Million Additional Grant Funding for AI Expansion
- Tevogen Highlights 74% Insider Ownership, Reinforcing Long-Term Vision
- Tevogen.AI Applauds U.S. Government’s AI Action Plan; Reaffirms Commitment to Accelerating AI Innovation in Healthcare
- Tevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active Peptides
- Tevogen.AI Targets Faster Time-to-Market with AI-Powered Patient Matching Following PredicTcell™ Alpha Launch
- Tevogen’s New Headquarters, Fully Funded by CEO, Centralizes R&D and AI Teams to Accelerate Innovation
- Tevogen CEO Contributes to Build-Out and First-Year Operations of New Headquarters
- Tevogen Expands Headquarters Amid Growth of AI and Generics & Biosimilars Initiatives
